Targeted Sequencing of Circulating Cell Free DNA Can Be Used to Monitor Therapeutic Efficacy of Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer Patients.

CONCLUSION: The mutation count of tumor-specific mutations can be a monitoring marker of TKI treatment in NSCLC patients.
PMID: 32576586 [PubMed - in process]

Source: Genomics Proteomics ... - June 25, 2020 Category: Genetics & Stem Cells Authors: Chiou CC, Wang CL, Luo JD, Liu CY, Ko HW, Yang CT Tags: Cancer Genomics Proteomics Source Type: research